Quantcast

Beacon Equity Research Clients

Below you will find a list of Beacon Equity Research's clients.
Click on the client's name to view information on that specific client.

QualityStocks Partner Clients

SmallCapVoice Clients
Stock Guru Clients

 


Untitled Document

Advanced Cell Technology, Inc. (ACTC)

Headquartered in Santa Monica, CA, Advanced Cell Technology, Inc. (ACTC) is a biotechnology company that develops cellular therapies for the treatment of both rare and common diseases. Using stem cell-based technologies and other proprietary methods in the field of regenerative medicine, ACTC aims to bring patient-specific therapies from the lab to the bedside so that they can help the millions of people affected by disease every day.

The company has three cellular product platforms based on ground breaking stem cell technology: Retinal Pigment Ephithelial (RPE) therapy, Myoblast stem cell therapy and the Hemangioblast (HG) platform. The company is in the process of commercializing its RPE for degenerative retinal disease and has secured two FDA clearances for Phase I/II clinical trials. ACT's Myoblast stem cell therapy is already Phase-II approved for the treatment of chronic heart failure, advanced cardiac disease, myocardial infarction, and ischemia. Finally, ACT'S Hemangioblast (HG) platform is being developed for the treatment of blood and cardiovascular diseases.

Overseeing ACT's development is an experienced management team and a world-class scientific team helmed by Interim Chairman and CEO Gary Rabin and Chief Scientific Officer Robert Lanza, M.D., respectively. For more information on the company please visit ww.advancedcell.com.

Beacon Equity Research Blog

Advanced Cell Technology, Inc. Message Board

 

The QualityStocks
Newsroom

Read the articles covering the biggest movers in the markets today.

Continue

Market
Basics

Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.

Continue

The QualityStocks Daily
Archives

Go back to see our previous newsletters and find out what you might have missed.

Continue